Risk Factors for Mortality in Patients with Pseudomonas aeruginosa Bacteremia: Clinical Impact of Antimicrobial Resistance on Outcome
Authors:
- 1 June 2011
- journal article
- Published by SAGE Publications in Microbial Drug Resistance
- Vol. 17 (2) , 305-312
Abstract
Despite the high prevalence of antimicrobial resistance among Pseudomonas aeruginosa bacteremia, the clinical consequence of resistance remains unclear. The purpose of this study was to identify predictors of mortality and evaluate the clinical impact of antimicrobial resistance on outcome in P. aeruginosa bacteremia. A retrospective cohort study including patients with P. aeruginosa bacteremia was performed. The risk factors for antimicrobial resistances were evaluated, and the impact of the respective resistances on mortality was assessed. Of 202 P. aeruginosa bacteremia cases, the resistance rates to ceftazidime, piperacillin, imipenem, fluoroquinolone, and aminoglycoside were 36.6%, 22.3%, 22.8%, 23.8%, and 17.8%, respectively. A prior use of fluoroquinolones and an indwelling urinary catheter were common risk factors for all types of antimicrobial resistance. The overall 30-day mortality rate was 25.2% (51/202), and the risk factors for mortality were corticosteroid use, nosocomial acquisition, polymicrobial infection, an increasing Charlson's weighted co-morbidity index, and intensive care unit care ( p < 0.05). As compared with the susceptible group, ceftazidime-, piperacillin-, or imipenem-resistant groups had a higher mortality ( p < 0.05). A multivariate analysis showed that resistance to ceftazidime or imipenem remained a significant factor associated with mortality (odds ratio, 2.96; 95% confidential interval, 1.20–7.31; and odds ratio, 2.74; 95% confidential interval, 1.02–7.31, respectively). Antimicrobial resistance, especially to ceftazidime or imipenem, adversely affected outcome in patients with P. aeruginosa bacteremia.Keywords
This publication has 28 references indexed in Scilit:
- Pandrug Resistance (PDR), Extensive Drug Resistance (XDR), and Multidrug Resistance (MDR) among Gram‐Negative Bacilli: Need for International Harmonization in TerminologyClinical Infectious Diseases, 2008
- Healthcare Epidemiology: Does Antibiotic Selection Impact Patient Outcome?Clinical Infectious Diseases, 2007
- Fluoroquinolone-Resistant Pseudomonas aeruginosa: Assessment of Risk Factors and Clinical ImpactThe American Journal of Medicine, 2006
- Multidrug-Resistant Pseudomonas aeruginosa : Risk Factors and Clinical ImpactAntimicrobial Agents and Chemotherapy, 2006
- Overview of Nosocomial Infections Caused by Gram-Negative BacilliClinical Infectious Diseases, 2005
- Bloodstream Infections Caused by Antibiotic-Resistant Gram-Negative Bacilli: Risk Factors for Mortality and Impact of Inappropriate Initial Antimicrobial Therapy on OutcomeAntimicrobial Agents and Chemotherapy, 2005
- Risk factors and clinical outcomes of nosocomial multi-drug resistant Pseudomonas aeruginosa infectionsJournal of Hospital Infection, 2004
- Pseudomonas aeruginosaBacteremia: Risk Factors for Mortality and Influence of Delayed Receipt of Effective Antimicrobial Therapy on Clinical OutcomeClinical Infectious Diseases, 2003
- Health Care–Associated Bloodstream Infections in Adults: A Reason To Change the Accepted Definition of Community-Acquired InfectionsAnnals of Internal Medicine, 2002
- Risk Factors for Imipenem-Resistant Pseudomonas aeruginosa among Hospitalized PatientsClinical Infectious Diseases, 2002